Eltrombopag patent expiry date?

When does the Eltrombopag patent expire?

Eltrombopag is an oral thrombopoietin receptor agonist used to treat certain blood disorders, including severe chronic immune thrombocytopenia and severe aplastic anemia [1].

According to DrugPatentWatch.com [2], the patent for Eltrombopag is owned by GlaxoSmithKline, and it has been the subject of a number of patent extensions and exclusivities over the years.

Can generic alternatives enter the market before the patent expires?

The FDA approved Eltrombopag in 2008, and at the time, it was granted a 5-year exclusivity period, which means that generic alternatives were not permitted on the market until 2013 [3].

Since then, the patent has been extended multiple times, with the most recent extension granted in 2020. However, these extensions are subject to certain conditions and may be revoked if certain criteria are not met.

What happens after the patent expires?

Once the patent expires, generic versions of Eltrombopag will be able to enter the market, which may lead to increased competition and lower prices. This can also enable biosimilar manufacturers to develop and market their own versions of the drug.

When will the Eltrombopag patent expire?

According to DrugPatentWatch.com, the Eltrombopag patent is set to expire in the United States in 2027, although this may be subject to change depending on any further extensions or revocations.

Sources:

[1] FDA approval letter for Eltrombopag (2008)

[2] DrugPatentWatch.com - Eltrombopag patent information

[3] FDA - Questions and Answers: Exclusivity Periods

Note that patent expiry dates are subject to change, and this information may not be up to date. Always consult the latest information from a reliable source for the most accurate and current information.